Fifth Third Bancorp Acquires 8,610 Shares of Boston Scientific Corporation $BSX

Fifth Third Bancorp increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 2.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 304,656 shares of the medical equipment provider’s stock after purchasing an additional 8,610 shares during the period. Fifth Third Bancorp’s holdings in Boston Scientific were worth $29,744,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Atticus Wealth Management LLC grew its stake in shares of Boston Scientific by 127.6% during the 3rd quarter. Atticus Wealth Management LLC now owns 4,086 shares of the medical equipment provider’s stock worth $399,000 after acquiring an additional 2,291 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its holdings in Boston Scientific by 4.3% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 517,472 shares of the medical equipment provider’s stock valued at $50,521,000 after purchasing an additional 21,386 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Boston Scientific by 0.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 1,221,843 shares of the medical equipment provider’s stock worth $119,289,000 after buying an additional 6,047 shares during the last quarter. ABN Amro Investment Solutions boosted its holdings in shares of Boston Scientific by 540.1% during the third quarter. ABN Amro Investment Solutions now owns 560,919 shares of the medical equipment provider’s stock worth $54,763,000 after acquiring an additional 473,283 shares during the period. Finally, HighTower Advisors LLC boosted its stake in Boston Scientific by 1.5% in the 3rd quarter. HighTower Advisors LLC now owns 182,557 shares of the medical equipment provider’s stock valued at $17,823,000 after purchasing an additional 2,685 shares during the period. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on BSX. Canaccord Genuity Group decreased their target price on shares of Boston Scientific from $131.00 to $112.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Stifel Nicolaus decreased their target price on Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. TD Cowen lowered their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Finally, National Bank Financial set a $115.00 target price on Boston Scientific in a report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $109.43.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 0.8%

BSX stock opened at $74.72 on Tuesday. The stock’s 50 day simple moving average is $90.56 and its 200 day simple moving average is $97.35. Boston Scientific Corporation has a fifty-two week low of $72.69 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The company has a market cap of $110.76 billion, a P/E ratio of 38.51, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The business’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.